Alerts will be sent to your verified email
Verify Email
HIKAL
|
Hikal
|
Suven Life Sciences
|
Cohance Lifesciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Total reactor capacity
|
3459.0 kL | n/a | n/a |
|
R&D as a % of Total Sales
|
4.42 % | 2132.75 % | 4.19 % |
|
Financials
|
|||
|
5 yr Average ROE
|
9.85 % | -82.05 % | 22.91 % |
|
5yr average Equity Multiplier
|
2.2 | 1.55 | 1.35 |
|
5yr Average Asset Turnover Ratio
|
0.77 | 0.05 | 0.56 |
|
5yr Avg Net Profit Margin
|
5.73 % | -1150.51 % | 30.38 % |
|
Price to Book
|
2.35 | 13.54 | 5.33 |
|
P/E
|
277.92 | 0.0 | 81.45 |
|
5yr Avg Cash Conversion Cycle
|
40.84 Days | 97.84 Days | 49.95 Days |
|
Inventory Days
|
60.35 Days | 10.88 Days | 74.21 Days |
|
Days Receivable
|
105.26 Days | 71.91 Days | 63.71 Days |
|
Days Payable
|
105.0 Days | 3.38 Days | 80.35 Days |
|
5yr Average Interest Coverage Ratio
|
4.65 | -373.47 | 49.87 |
|
5yr Avg ROCE
|
12.68 % | -82.34 % | 27.5 % |
|
5yr Avg Operating Profit Margin
|
16.33 % | -1227.3 % | 40.14 % |
|
5 yr average Debt to Equity
|
0.65 | 0.0 | 0.06 |
|
5yr CAGR Net Profit
|
-7.37 % | 17.38 % | -5.86 % |
|
5yr Average Return on Assets
|
4.51 % | -54.63 % | 17.54 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
68.85 % | 67.36 % | 57.49 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.08 % | 2.38 % | -2.51 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
2.99 % | 2.07 % | 8.21 % |
|
Hikal
|
Suven Life Sciences
|
Cohance Lifesciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|